Karol Sikora
[back] Experts
[2013 Jan] Sorry, but there's no such thing as
a diet that cures cancer
[April 2007] Don't panic about HRT
"A current flagrant conflict of interest is exemplified by Dr. Karol Sikora, recently resigned from the WHO’s cancer campaign, and who now holds the dual positions of Professor of Cancer Medicine at the Hammersmith Hospital and Vice President of Oncology at Pharmacia and UpJohn. Sikora has recently become closely associated with the cancer charities."--Dr Epstein MD
[2008] 'Karol Sikora is Medical Director of CancerPartnersUK which is creating the largest UK cancer network as a series of joint ventures with NHS Trusts. He is Professor of Cancer Medicine and honorary Consultant Oncologist at Imperial College School of Medicine, Hammersmith Hospital, London. He is Scientific Director of Medical Solutions PLC, Britain’s leading cancer diagnostic company. He has recently been appointed Dean of Britain’s first independent Medical School at the University of Buckingham....From 1997 to 1999 he was Chief of the WHO Cancer Programme and from 1999 to 2002, Vice President, Global Clinical Research (Oncology) at Pharmacia Corporation.' http://www.karolsikora.com/
Ryke Geerd Hamer, M.D.
Chemotherapy
|
Qualifications and distinctions:
|
http://www.prostatecancertreatment.co.uk/about-us/karol-sikora
Pfizer Inc and Pharmacia Corporation began operating as a unified company on April 16, 2003. 2003: Pfizer and Pharmacia Merger
Pharmacia Corporation. The Group's principal activity is to develop, manufacture and sell pharmaceutical products. Prescription pharmaceuticals include general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. The Group also operates in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the Group include pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. The Group operates in North America, Europe, Africa, Asia and Latin America. The Group discontinued the operations of Monsanto and Artificial Sweetener Ingredient Business in 2002. Prescription pharmaceutical products accounted for 86% of 2002 revenues and Other pharmaceutical products, 14%. Prescription pharmaceutical products accounted for 86% of 2002 revenues and Other pharmaceutical products, 14% http://www.business.com
Pharmacia Corporation is a first-tier global pharmaceutical company with an
industry-leading growth rate, a robust product portfolio, a high-potential
research and development pipeline, and a dynamic agricultural subsidiary in
Monsanto Company.
Pharmacia Corporation was created
in April 2000 through the merger of Pharmacia & Upjohn with Monsanto Company and
its G.D. Searle unit. Pharmacia employs 59,000 people worldwide and has
research, manufacturing and administrative sales operations in more than 60
countries.
Pharmacia is implementing a new,
comprehensive system for managing environmental, safety and health (ESH) issues
and has adopted a series of ESH standards to guide operations worldwide. These
are described in a detailed Environment, Safety and Health Report that includes
the corporate ESH policy, discussions of the company's approach to some
significant issues, stories about successful ESH initiatives at the local level
and a detailed accounting of Pharmacia waste generation and waste management
worldwide.
http://www.scripophily.net/gdsearcom.html
[2003] Pfizer, Pharmacia Will
Divest Assets to Settle FTC Charges Pfizer Inc.,
and Pharmacia Corporation will divest pharmaceutical products in nine separate
product markets to different third parties to settle Federal Trade Commission
charges that the merger of Pharmacia and Pfizer likely would have
anticompetitive effects in those product markets and violate antitrust laws......Pfizer,
is the largest pharmaceutical company in the United States, the largest animal
health pharmaceutical company in the world, and one of the world's largest
providers of consumer health products. It had worldwide revenues of over $32
billion in 2001. Pfizer, a Delaware corporation, is based in New York City.
Pharmacia, based in Peapack, New Jersey, is engaged in the research,
development, manufacture, and sale of pharmaceutical products, animal health
products, fine chemicals, and consumer health products. In 2001, the company
reported sales revenues of over $13.8 billion, with $11.9 billion coming from
prescription pharmaceutical sales. Pfizer proposes to acquire Pharmacia in a
deal valued at approximately $60 billion.
According to the FTC, there are three
significant competitors in the combination HRT market: Wyeth, Pfizer, and
Pharmacia.